806results about "Library screening" patented technology

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

Compositions which are fragrant and contain at least a member set culled from a library of compositions, each being comprised of sub-combinations of selected terpenes. Fragrances that mimic that of various states of organic and synthetic aromatics including products, processes and those from non-combusted plant products, among other things, uniquitous products, processes, medicinals, and related moieties leverage databases of all known terpene groupings are offered for consideration, and have been provided, according to the instant teachings.

Disclosed herein are compositions of retroviruses and methods of using the same for gene delivery, wherein the retroviruses comprise a viral envelope protein comprising at least one mutation that diminishes its native function, a non-viral membrane-bound protein comprising a membrane-bound domain and an extracellular targeting domain.

A method for training a deep learning model configured for virtual screening of molecules for micro ribonucleic acid (miRNA) drug discovery includes creating a training dataset including a plurality of assay datasets. The method also includes training the deep learning model to learn a plurality of tasks; performing, using the deep learning model, inference for the respective task associated with at least one miRNA assay dataset; and evaluating respective performance metrics associated with the respective predictions for each of the plurality of tasks. The method further includes selecting a set of the plurality of assay datasets for training; and training the deep learning model to learn a set of the plurality of tasks using the set of the plurality of assay datasets. The trained deep learning model is configured to predict molecules capable of affecting a target miRNA.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

Compositions of retroviruses and methods of using the same for gene delivery, wherein the retroviruses comprise a viral envelope protein comprising at least one mutation that diminishes its native function, a non-viral membrane-bound protein comprising a membrane-bound domain and an extracellular targeting domain.

The invention provides a system and a method for screening Cas protein mutants capable of identifying different PAM sequences, and belongs to the technical field of bioengineering. The system comprises a Cas protein mutant screening vector and an sgRNA expression vector, the Cas protein mutant screening vector comprises the following expression elements: a Cas protein coding gene, a plasmid replicon and a first resistance screening tag expression cassette; the sgRNA expression vector comprises the following expression elements: a plasmid replicon, a second resistance screening tag expression cassette, a third resistance screening tag expression cassette and an sgRNA expression cassette. According to the system and the method, aiming at the problem that the efficiency of identifying PAM sequences except NGG by wild type spCas9 protein is low, an active Cas9 mutant capable of identifying PAM sites except NGG is screened out, and the application field and the editing efficiency of a CRISPR gene editing system can be greatly expanded.

The invention provides a nucleic acid aptamer and a screening method thereof, the aptamer is of an oligonucleotide DNA structure, the nucleotide sequence of the nucleic acid aptamer is the nucleotide sequence of any DNA fragment as shown in SEQ ID NO: 1-9, and the nucleic acid aptamer can specifically target cardiac muscle cells (CMs). According to the invention, a new strategy can be provided for clinical treatment of cardiovascular diseases, and meanwhile, bioactive molecules such as microRNA (miRNA), small interfering RNA (small interfering RNA, siRNA), lipidosome, microspheres, microcapsules and the like can be carried to be used as an intracellular drug delivery tool.

The invention belongs to the technical field of food and feed analysis and detection, and particularly provides a nano antibody for detecting bacitracin methylene salicylate, and the nano antibody comprises a nano antibody BMD-BA19 and a nano antibody BMD-CA45; the amino acid sequence of a VHH chain of the nano antibody BMD-BA19 is as shown in SEQ ID NO: 1, and the amino acid sequence of a VHH chain of the nano antibody BMD-CA45 is as shown in SEQ ID NO: 2. The bacitracin methylene salicylate serves as a research object, after the bacitracin methylene salicylate is coupled with protein, an alpaca is immunized, two nano antibodies resisting bacitracin methylene salicylate are obtained through screening with a phage display technology, and a material is provided for establishing a bacitracin methylene salicylate detection method.

An automated high throughput screening platform for identification of compounds and genomic constructs having mitochondrial function modulating activity and compounds so identified are provided. Use of such compounds for modulating mitochondrial function are also disclosed. A high-throughput screening method of determining genetic mechanisms of action for therapeutic or toxic agents in genetic or pharmacologic models of disease are also provided.

A system and method for the high throughput screening of small molecule-protein interactions includes first immobilizing selected small molecules on a solid matrix. Immobilization is preferably made by photo affinity labelling in which a linker used to bind the small molecule to the matrix. A cDNA library is established from a broad array of human tissues. The tissue mRNA is converted to cDNA and transferred to a phage genome to make a phage display library which is mixed with small molecules coupled to the beads and incubated. The incubation mixture is washed to remove unbound phage including non-specific and weak binders. The bound phage are amplified and are used in the next round of biopanning. The biopanning cycles are repeated followed by PCR of individual plaques selected from the final biopanning round. The PCR products are barcoded from each small molecule experiment and are pooled followed by Nextgen sequencing.

Compositions, methods and systems for targeted delivery using one or more shuttles operably linked to one or more cargos (e.g., cargo polypeptides, e.g., cargo oligonucleotides) and subsequent quantification of an abundance of one or more cargos (e.g, proteins) in a mixture (e.g., a complex mixture (e.g., in vivo)) or in a specific cell, tissue, or organ of interest (e.g., in vivo) using barcodes (e.g., peptide barcodes), binders (e.g., polypeptide binders), and binding agents (e.g., phage) are provided herein.

A method of analyzing a tumor sample comprising:(a) acquiring a library comprising a plurality of tumor members from a tumor sample;(b) contacting the library with a bait set to provide selected members;(c) acquiring a read for a subgenomic interval from a tumor member from said library;(d) aligning said read; and(e) assigning a nucleotide value (e.g., calling a mutation) from said read for the preselected nucleotide position, thereby analyzing said tumor sample.

Kits and methods of analyzing macromolecules, including peptides, polypeptides, and proteins, using nucleic acid coding are disclosed. Sample analysis kits employ nucleic acid coding and / or nucleic acid recording of molecular interactions and / or reactions, such as recognition events (e.g., between antigens and antibodies, between modified terminal amino acid residues, or between small molecules or peptide therapeutic agents and targets, etc. Additional barcoding reagents, such as reagents for cycle-specific barcoding (e.g., "timing"), compartment barcoding reagents, combined barcoding reagents, spatial barcoding reagents, or any combination thereof, may be included in the kit. The sample may comprise macromolecules, including peptides, polypeptides, and proteins, and the recording may produce molecular interaction and / or reaction information, and / or polypeptide sequence information. The kits can be used for high throughput, multiplexing and / or automated analysis, and are suitable for the analysis of proteomes or subsets thereof.

Antimicrobial peptides (AMPs) exhibiting broad spectrum antimicrobial activity are described. Such peptides are useful in treating or preventing infections and other conditions, and are of special interest for treating antibiotic-resistant bacterial pathogens, viruses, fungi, and other pathogens, or for anti-cancer applications. Treatment or prevention of infection in humans or animals is described as well as uses and methods for disinfecting or prevention of growth of microbes on a surface, a material, or in an environment, such as for environmental remediation. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. Two high throughput bioinformatics approaches leading to (1) de novo design of numerous antimicrobial peptides, and (2) identification of numerous antimicrobial peptides from known genomic sequences are described.

The invention discloses preparation and application of a biological material for targeted therapy of osteoarthritis, and the preparation method comprises the following steps: according to a phage screening principle, after phages are combined with cartilage cells, washing off phages which are not combined with the cartilage cells, are not firmly combined with the cartilage cells and are non-specifically combined with the cartilage cells; eluting the specifically bound bacteriophage with glycine acid; after the specific binding bacteriophage is amplified by escherichia coli, screening is carried out by utilizing a bacteriophage display technology and cartilage cells; the preparation method comprises the following steps: preparing a small-size porous microgel loaded drug by adopting a multiple Pickering emulsion template method; and grafting the screened cartilage targeting peptide to the surface of the porous hydrogel microsphere to obtain the HS-SP microsphere. According to the invention, the problem of OA targeting can be effectively solved by adopting a phage display technology, and a drug is precisely targeted and delivered to an OA lesion region; the porous hydrogel microspheres with small particle size are prepared by adopting a multiple Pickering emulsion method, so that the use of a large number of surfactants is avoided, and the efficient loading and release of drugs can be realized.

The invention is directed to a conjugate having the general formula (I)Xn—P—YmBo  (I)with X is an detection moiety,P is a spacer unit,Y an antigen recognizing moiety,B an oligonucleotide comprising 2 to 100 nucleotide residuesand n, m, o are independent integers between 1 and 100wherein P and B are covalently bound to Y and X is covalently bound to P and wherein X is erasable.Further, the invention is directed to a library of such conjugates and a method of detecting target cells utilizing the conjugates or the library of conjugates.

In traditional plant breeding approaches, chemical mutagenesis may be utilized to introduce nucleotide substitutions at random in the genome of a plant, i.e. without possibilities to control the sites of nucleotide changes. Because of genome complexities, the statistical probability is extremely little when it comes to finding a predetermined nucleotide substitution. The present invention, however, demonstrates how a novel, alternative use of digital polymerase chain reaction (dPCR), preferably droplet dPCR (ddPCR), is developed to exploit finding of specific nucleotide substitutions in mutated genes. The entire platform comprises a screening method with a library of mutagenized organisms, digital PCR-based systems and a set-up to propagate and analyze identified, mutated organisms.